Riding China’s supportive policies for rare disease and breakthrough therapies, including cell and gene therapies, Takeda Pharmaceutical Co. Ltd. has deepened its Chinese pharma industry ties by obtaining exclusive rights to commercialize Belief Biomed Inc.'s hemophilia B gene therapy BBM-H901 in the country, along with Hong Kong SAR and Macau SAR.
Takeda Chooses Belief For First Commercial Gene Therapy Tie-Up In China
Sourcing Chinese Innovation Trend Continues
A new gene therapy deal between Takeda and Belief signals multinationals are continuing to increase the pace of collaboration with Chinese partners as a source of innovation.
